Enhanced Conolidine: Medical Scientist Clint Winters Announces Patent Filing on CONOCB2™, A Novel Conolidine Pain Relief Active Ingredient with Natural Endocannabinoids

Winters Biotechnology, led by Medical Scientist Clint Winters, has announced patent filings in relation to CONOCB2™, an enhanced version of pain relieving conolidine that includes naturally occurring Endocannabinoids. This patent builds upon the CONO1000™ patent filing which marked the first introduction of natural conolidine in the world health market.

ALPHARETTA, Ga., Jan. 11, 2022 /PRNewswire-PRWeb/ — Winters Biotechnology has announced patent filings for CONOCB2™, a novel dietary ingredient featuring an enhanced version of the conolidine alkaloid formulated for greater natural pain relief.

This announcement comes on the heels of the patent filing for CONO1000™, the first ever natural conolidine ingredient to hit the world market.

For years, conolidine, a naturally occurring alkaloid found inside the bark of the Tabernaemontana divaricata tree, has been studied for its ability to effectively relieve pain.

A synthetic version of conolidine was initially investigated in 2011 and was compared therapeutically to morphine without exhibiting side effects or addiction risk in rat models.

In 2019, Australian scientists discovered it had similar pain-killing modalities as CBD.

Then in early 2021, scientists reconfirmed its ability to significantly relieve chronic pain as they pinpointed its ability to affect the ACKR3/CXCR7 receptor.

In 2017 Clint Winters became the first medical scientist in the world to explore the natural extraction of conolidine from the Tabernaemontana divaricata tree.

This extraction became public knowledge in 2019.

The evolution of these non synthetic conolidine ingredients have been under heavy testing by Winters Biotechnology for nearly 4 years.

There is strong evidence of it being a successful natural relief ingredient after private clinical testing involving nearly 30,000 voluntary users over multiple years.

In 2021, Clint Winters and Winters Biotechnology announced patents on a novel nutrient extraction system named the DualPolar™ extraction method, which is now being used to create a full-spectrum extraction of Tabernaemontana divaricata, including the conolidine alkaloid.

This extraction was named CONO1000™.

Conolidine CONOCB2™ is an enhanced version of CONO1000™ that has been formulated to also affect the endocannabinoid system in addition to the Opioid Receptors in the brain.

The purpose of the innovation is to create a “full spectrum’ pain relief ingredient that will be highly effective against many types of common daily pain.

Continued: https://www.prweb.com/releases/enhanced_conolidine_medical_scientist_clint_winters_announces_patent_filing_on_conocb2_a_novel_conolidine_pain_relief_active_ingredient_with_natural_endocannabinoids/prweb18427664.htm